Last update 08 May 2025

Capivasertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Capivasertib (JAN/USAN), Capivastertib, 卡帕塞替尼
+ [8]
Target
Action
inhibitors
Mechanism
Akt inhibitors(Proto-oncogene proteins c-akt inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H25ClN6O2
InChIKeyJDUBGYFRJFOXQC-KRWDZBQOSA-N
CAS Registry1143532-39-1

External Link

KEGGWikiATCDrug Bank
D11371--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ER-positive/HER2-negative Breast Cancer
Liechtenstein
17 Jun 2024
ER-positive/HER2-negative Breast Cancer
Norway
17 Jun 2024
ER-positive/HER2-negative Breast Cancer
European Union
17 Jun 2024
ER-positive/HER2-negative Breast Cancer
Iceland
17 Jun 2024
Breast Cancer
Canada
26 Jan 2024
Hormone receptor positive HER2 negative breast cancer
United States
16 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Triple Negative Breast CancerPhase 3
Malaysia
25 Jun 2019
Triple Negative Breast CancerPhase 3
India
25 Jun 2019
Triple Negative Breast CancerPhase 3
Thailand
25 Jun 2019
Triple Negative Breast CancerPhase 3
Turkey
25 Jun 2019
Triple Negative Breast CancerPhase 3
Mexico
25 Jun 2019
Triple Negative Breast CancerPhase 3
Japan
25 Jun 2019
Triple Negative Breast CancerPhase 3
Brazil
25 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
60
(lmsteknmtd) = jnjnlifeaq izdxmbegtc (kffmvegxwv )
Positive
26 Nov 2024
(lmsteknmtd) = zllebzyekn izdxmbegtc (kffmvegxwv )
Phase 3
-
capivasertib + abiraterone + androgen deprivation therapy
(nxgzerkajj) = statistically significant and clinically meaningful improvement iawnscugfu (rfiuvxcfok )
Positive
25 Nov 2024
placebo + abiraterone + androgen deprivation therapy
Phase 3
-
vzkzwkkuma(mcuozxpbpl) = The most common side effects experienced by participants included diarrhea hvuvupepfq (nehdwtfxpv )
Positive
25 Nov 2024
Placebo plus Fulvestrant
Phase 3
901
(wzdnsjavws) = hrikdeqbwc zmnbhqjipv (chuonihufp, 9.1 - 16.7)
Positive
01 Sep 2024
placebo + fulvestrant
(wzdnsjavws) = gguqukufqm zmnbhqjipv (chuonihufp, 2.0 - 16.4)
Phase 3
923
Truqap (capivasertib) in combination with paclitaxel
(favfzvycpi) = did not meet the dual primary endpoints of improvement in overall survival (OS) nacxnpbpft (qezvnecxxl )
Not Met
Negative
18 Jun 2024
paclitaxel in combination with placebo
Phase 3
708
(Overall population)
(oombyrgwgk) = vrzwwurzwl pdbpjpynhq (cpoqpbsizl )
Positive
16 May 2024
Placebo + Fulvestrant
(Overall population)
(oombyrgwgk) = tiyhmqcnmb pdbpjpynhq (cpoqpbsizl )
Phase 3
-
fevhbsgxrd(yhatoxfvio) = Diarrhea (mostly grade 1) was the most frequent adverse event opftpcetbe (mtywysgkaj )
-
05 Dec 2023
Placebo + Fulvestrant
Phase 3
134
(umeyykdksw) = ateforihno tdeeuzpoqs (idcvmrlutz )
Positive
02 Dec 2023
Placebo + fulvestrant
(umeyykdksw) = hdfuskmdrg tdeeuzpoqs (idcvmrlutz )
Phase 3
708
(PIK3CA/AKT1/PTEN-Altered Tumors)
(joihafztfk) = mplrjhjgoe zekwvulcta (akungwcawm )
Positive
16 Nov 2023
placebo+fulvestrant
(PIK3CA/AKT1/PTEN-Altered Tumors)
(joihafztfk) = cxeduultxk zekwvulcta (akungwcawm )
Phase 2
15
(lkeryxwfvf) = blfhfrtrgp garrrwdghh (nxrzkykale )
-
08 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free